Dr. Joe Lennerz, Chief Scientific Officer of BostonGene and a pathologist by training, joins me on Healthcare Unfiltered to break down next-generation sequencing (NGS) in simple terms, discussing why some patients undergo NGS while others do not, along with its advantages and limitations.
My guest also explores the impact of NGS on treatment pathways, the practicality of minimal residual disease (MRD) detection, liquid biopsy, and circulating tumor DNA (ctDNA), and whether immediate action should be taken after MRD detection. Additionally, Dr. Lennerz examines multi-cancer early detection technologies, who should be tested, and the future need for regulatory oversight in this rapidly advancing field.
N/A
Chadi welcomes Dr. Andrea Apolo, an internationally recognized leader in bladder cancer research from the National Cancer Institute. Dr. Apolo shares her expertise on recent advancements in urothelial cancer therapy, including key breakthroughs in checkpoint inhibition that have marked a significant turning point in treatment. The conversation delves into optimal sequencing and combination strategies for
Dr. Joe Mikhael, Chief Medical Officer of the International Myeloma Foundation (IMF) and Professor at TGen, takes us beyond his medical career to explore the personal experiences that have shaped his journey in oncology. Dr. Mikhael discusses the IMF’s targeted strategies for reducing health disparities among diverse ethnic and racial groups affected by myeloma, shedding
Tom Beer, Chief Medical Officer of the Multi-Cancer Early Detection (MCED) program at Exact Sciences, delves into the groundbreaking science behind MCED tests, which use advanced biomarkers for early detection of multiple cancer types. On this Healthcare Unfiltered episode, he explains who may be eligible for these tests, how to interpret results to avoid unnecessary
